Journal
NEURODEGENERATIVE DISEASE MANAGEMENT
Volume 3, Issue 1, Pages 43-51Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NMT.12.75
Keywords
-
Categories
Funding
- NIH [AG016570, R01AG09009, R01AG033673, P30AG035982]
- Alzheimer's Association [NIRG-12242511]
- John Douglas French Foundation
- Sidell-Kagan Foundation
- Michael J Fox Foundation. JM Burns receives research support from the NIH [P30AG035982, R01AG034614, R01AG03367, U10NS077356, UL1TR000001]
- publishing 'Early Diagnosis and Treatment of Mild Cognitive Impairment' (Wiley Press, NJ, USA)
- Atlas of Investigation and Diagnosis' (Clinical Publishing, Oxford, UK)
- Novartis speakers' bureau and as a consultant for PRA International (Reading, UK)
- Jannsen, Wyeth, Danone, Pfizer and Baxter
Ask authors/readers for more resources
Demonstration of brain accumulation of fibrillar amyloid-beta protein via PET with amyloid-specific ligands may support the diagnosis of Alzheimer's disease (AD). There is increasing recognition of the potential use of amyloid imaging to detect the pathology of AD in vivo in individuals with no ostensible cognitive impairment. Research use of amyloid PET in cognitively normal patients will be key to the pursuit of therapies able to delay cognitive impairment and dementia due to AD. We review the pros and cons of disclosing amyloid imaging results to cognitively normal individuals in clinical and research settings and provide draft recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available